1. Home
  2. SNY vs MMC Comparison

SNY vs MMC Comparison

Compare SNY & MMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNY
  • MMC
  • Stock Information
  • Founded
  • SNY 1994
  • MMC 1871
  • Country
  • SNY France
  • MMC United States
  • Employees
  • SNY N/A
  • MMC N/A
  • Industry
  • SNY Biotechnology: Pharmaceutical Preparations
  • MMC Specialty Insurers
  • Sector
  • SNY Health Care
  • MMC Finance
  • Exchange
  • SNY Nasdaq
  • MMC Nasdaq
  • Market Cap
  • SNY 120.2B
  • MMC 104.0B
  • IPO Year
  • SNY N/A
  • MMC N/A
  • Fundamental
  • Price
  • SNY $50.74
  • MMC $215.13
  • Analyst Decision
  • SNY Buy
  • MMC Hold
  • Analyst Count
  • SNY 2
  • MMC 15
  • Target Price
  • SNY $57.50
  • MMC $229.40
  • AVG Volume (30 Days)
  • SNY 2.3M
  • MMC 1.9M
  • Earning Date
  • SNY 01-30-2025
  • MMC 01-30-2025
  • Dividend Yield
  • SNY 4.01%
  • MMC 1.51%
  • EPS Growth
  • SNY N/A
  • MMC 16.97
  • EPS
  • SNY 4.00
  • MMC 8.11
  • Revenue
  • SNY $54,031,898,261.00
  • MMC $23,945,000,000.00
  • Revenue This Year
  • SNY $0.88
  • MMC $8.04
  • Revenue Next Year
  • SNY $6.28
  • MMC $10.44
  • P/E Ratio
  • SNY $25.52
  • MMC $26.55
  • Revenue Growth
  • SNY 6.01
  • MMC 7.84
  • 52 Week Low
  • SNY $45.22
  • MMC $188.31
  • 52 Week High
  • SNY $58.97
  • MMC $235.50
  • Technical
  • Relative Strength Index (RSI)
  • SNY 63.19
  • MMC 51.50
  • Support Level
  • SNY $47.88
  • MMC $207.21
  • Resistance Level
  • SNY $51.08
  • MMC $211.95
  • Average True Range (ATR)
  • SNY 0.66
  • MMC 3.16
  • MACD
  • SNY 0.29
  • MMC 0.96
  • Stochastic Oscillator
  • SNY 89.67
  • MMC 78.51

About SNY Sanofi ADS

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

About MMC Marsh & McLennan Companies Inc.

Marsh McLennan is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (a management and economic consultancy). About half of its revenue is generated outside the US.

Share on Social Networks: